• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Neuronetics Announces Appointment of Joseph H. Capper to its Board of Directors

    12/29/22 4:29:00 PM ET
    $BEAT
    $STIM
    Medical/Dental Instruments
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $BEAT alert in real time by email

    MALVERN, Pa., Dec. 29, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help with the best neurohealth therapies in the world, today announced the appointment of Joseph H. Capper to its Board of Directors and as a member of the Audit Committee effective January 1, 2023.

    "Joe is well known and extremely well regarded in the med-tech community for his ability to advance company goals," said Rob Cascella, Chairman of the Board of Neuronetics. "His depth of experience with public companies and his passion for innovative medical technologies will further strengthen our Board, benefit our company, and help the patients served by our mental health providers."

    Mr. Capper brings nearly 30 years of med-tech and life sciences experience to the Company. Most recently, he served as President and Chief Executive Officer of BioTelemetry, Inc, (NASDAQ:BEAT), the successor to CardioNet, Inc., and Home Diagnostics, Inc. (NASDAQ:HDIX). Prior to Home Diagnostics, Joe was President and Chief Executive Officer of CCS Medical Inc., a private company. Earlier, Joe spent nine years with Bayer Corporation, ultimately becoming National Sales Director of the Diabetic Products Division. Joe also has a distinguished service record, having served in the U.S. Navy as a combat aviator and later as a congressional liaison. Joe received his undergraduate degree in accounting from West Chester University and an MBA in International Finance from George Washington University.

    "The accelerating decline of mental health in the wake of the pandemic makes Neuronetics' technology more relevant than ever," said Mr. Capper. "I am impressed by the organization's mission to transform neurohealth and its passion for that purpose. I look forward to contributing to the company's future success."

    About Neuronetics

    Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is redefining patient and physician expectations with its NeuroStar Advanced Therapy for Mental Health. NeuroStar is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication hasn't helped. NeuroStar is FDA-cleared for adults with major depressive disorder (MDD), as an adjunct for adults with obsessive-compulsive disorder (OCD), and to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression). NeuroStar Advanced Therapy is the leading transcranial magnetic stimulation (TMS) treatment for MDD in adults with over 5 million treatments delivered. NeuroStar is backed by the largest clinical data set of any TMS system for depression, including the world's largest depression Outcomes Registry. Neuronetics is committed to transforming lives by offering an exceptional treatment that produces extraordinary results. For safety and prescribing information, www.neurostar.com.

    "Safe harbor" statement under the Private Securities Litigation Reform Act of 1995:

    Statements in the press release regarding Neuronetics, Inc. (the "Company") that are not historical facts constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may be identified by terms such as "outlook," "potential," "believe," "expect," "plan," "anticipate," "predict," "may," "will," "could," "would" and "should" as well as the negative of these terms and similar expressions. These statements are subject to significant risks and uncertainties and actual results could differ materially from those projected. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this release. These risks and uncertainties include, without limitation, risks and uncertainties related to: the Company's ability to achieve or sustain profitable operations due to its history of losses; the Company's reliance on the sale and usage of its NeuroStar Advanced Therapy System to generate revenues; the scale and efficacy of the Company's salesforce; availability of coverage and reimbursement from third-party payors for treatments using the Company's products; physician and patient demand for treatments using the Company's products; developments in respect of competing technologies and therapies for the indications that the Company's products treat; product defects; the Company's ability to obtain and maintain intellectual property protection for its technology; developments in clinical trials or regulatory review of NeuroStar Advanced Therapy System for additional indications; and developments in regulation in the United States and other applicable jurisdictions. For a discussion of these and other related risks, please refer to the Company's recent SEC filings which are available on the SEC's website at www.sec.gov.  These forward-looking statements are based on the Company's expectations and assumptions as of the date of this press release. Except as required by law, the Company undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events or changes in the Company's expectations.

    Investor Contact:

    Mark R. Klausner

    Westwicke Partners

    443-213-0501

    [email protected]

    Media Contact:

    EvolveMKD

    646-517-4220

    [email protected]



    Primary Logo

    Get the next $BEAT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BEAT
    $STIM

    CompanyDatePrice TargetRatingAnalyst
    Neuronetics Inc.
    $STIM
    8/13/2024Outperform → Mkt Perform
    William Blair
    Heartbeam Inc.
    $BEAT
    12/20/2021$9.00Speculative Buy
    Benchmark
    Neuronetics Inc.
    $STIM
    10/14/2021$18.00 → $12.00Market Outperform
    JMP Securities
    Neuronetics Inc.
    $STIM
    10/13/2021Outperform → Mkt Perform
    William Blair
    Neuronetics Inc.
    $STIM
    10/13/2021Buy → Neutral
    BTIG
    More analyst ratings

    $BEAT
    $STIM
    Leadership Updates

    Live Leadership Updates

    See more
    • HeartBeam Appoints CEO Robert Eno to Board of Directors to Support U.S. Commercialization and Growth

      Board expansion reflects Company's commitment to leadership and innovation in remote cardiac monitoring HeartBeam, Inc., (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced the appointment of Chief Executive Officer, Robert Eno, to its Board of Directors. As the Company continues to make significant advancements towards commercial readiness, the Board elected to expand from eight to nine members to accommodate this addition. Mr. Eno joined HeartBeam as President in January 2023 and was appointed CEO in October 2024. With over 30 years of experience in the medical technology industry, he has a proven

      5/5/25 7:00:00 AM ET
      $BEAT
      Medical/Dental Instruments
      Health Care
    • HeartBeam Announces FDA Clearance for At-Home, High-Fidelity Heart Monitoring Technology

      First cable-free, ambulatory ECG that captures the heart's electrical signals from three distinct directions for high-fidelity data collection and advanced diagnostics Patients can have the credit card-sized device with them at all times, ready to record an ECG whenever they feel symptoms and reduce delays in care Company to initiate Early Access Program to gain important patient and physician feedback on the use of the system in preparation for commercial launch HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced that the US Food and Drug Administration (FDA) has granted 510(k) cl

      12/16/24 8:31:00 AM ET
      $BEAT
      Medical/Dental Instruments
      Health Care
    • HeartBeam Appoints Robert Eno as Chief Executive Officer in Preparation for US Commercialization

      Industry leader brings extensive experience in developing go-to-market strategies for breakthrough products and delivering growth Founder and current CEO Branislav Vajdic named President to focus on advancing the Company's groundbreaking vector-based technology for heart health, including AI applications HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful insights wherever the patient is, announced that Robert Eno has been appointed Chief Executive Officer (CEO), effective Monday, October 21, 2024. The seasoned MedTech executive joined HeartBeam as President in January 2023 and will lead as the Company continues to work

      10/17/24 8:31:00 AM ET
      $BEAT
      Medical/Dental Instruments
      Health Care

    $BEAT
    $STIM
    SEC Filings

    See more
    • SEC Form DEF 14A filed by Heartbeam Inc.

      DEF 14A - HeartBeam, Inc. (0001779372) (Filer)

      5/28/25 9:12:56 PM ET
      $BEAT
      Medical/Dental Instruments
      Health Care
    • SEC Form 8-K filed by Neuronetics Inc.

      8-K - Neuronetics, Inc. (0001227636) (Filer)

      5/28/25 7:11:18 AM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • SEC Form PRE 14A filed by Heartbeam Inc.

      PRE 14A - HeartBeam, Inc. (0001779372) (Filer)

      5/16/25 9:10:31 PM ET
      $BEAT
      Medical/Dental Instruments
      Health Care

    $BEAT
    $STIM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Neuronetics downgraded by William Blair

      William Blair downgraded Neuronetics from Outperform to Mkt Perform

      8/13/24 10:26:16 AM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Benchmark initiated coverage on BioTelemetry with a new price target

      Benchmark initiated coverage of BioTelemetry with a rating of Speculative Buy and set a new price target of $9.00

      12/20/21 7:19:06 AM ET
      $BEAT
      Medical/Dental Instruments
      Health Care
    • JMP Securities reiterated coverage on Neuronetics with a new price target

      JMP Securities reiterated coverage of Neuronetics with a rating of Market Outperform and set a new price target of $12.00 from $18.00 previously

      10/14/21 8:41:45 AM ET
      $STIM
      Medical/Dental Instruments
      Health Care

    $BEAT
    $STIM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Rosengarten Megan was granted 30,000 shares, increasing direct ownership by 27% to 140,890 units (SEC Form 4)

      4 - Neuronetics, Inc. (0001227636) (Issuer)

      5/27/25 5:00:18 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Director Conley Sheryl L was granted 30,000 shares, increasing direct ownership by 16% to 214,390 units (SEC Form 4)

      4 - Neuronetics, Inc. (0001227636) (Issuer)

      5/27/25 5:00:13 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Director Amin Avinash was granted 30,000 shares, increasing direct ownership by 240% to 42,500 units (SEC Form 4)

      4 - Neuronetics, Inc. (0001227636) (Issuer)

      5/27/25 5:00:15 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care

    $BEAT
    $STIM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Neuronetics Inc.

      SC 13D - Neuronetics, Inc. (0001227636) (Subject)

      12/17/24 9:15:11 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Neuronetics Inc.

      SC 13G/A - Neuronetics, Inc. (0001227636) (Subject)

      11/14/24 1:42:23 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Neuronetics Inc.

      SC 13G/A - Neuronetics, Inc. (0001227636) (Subject)

      11/14/24 11:17:47 AM ET
      $STIM
      Medical/Dental Instruments
      Health Care

    $BEAT
    $STIM
    Financials

    Live finance-specific insights

    See more
    • HeartBeam to Host First Quarter 2025 Results Conference Call on Tuesday, May 13, 2025 at 4:30 p.m. Eastern Time

      HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, will hold a conference call on Tuesday, May 13, 2025 at 4:30 p.m. Eastern time to discuss its results for the first quarter ended March 31, 2025, and will be providing updates on regulatory initiatives, commercial-readiness activities and anticipated milestones. A press release detailing these results will be issued prior to the call. HeartBeam CEO Robert Eno and CFO Timothy Cruickshank will host the conference call, followed by a question-and-answer period. The conference call will be accompanied by a presentation, which can be viewed during the web

      5/1/25 8:31:00 AM ET
      $BEAT
      Medical/Dental Instruments
      Health Care
    • Neuronetics to Report First Quarter 2025 Financial and Operating Results and Host Conference Call

      MALVERN, Pa., April 22, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that it plans to release first quarter 2025 financial and operating results prior to market open on Tuesday, May 6, 2025. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day. The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-server.com/mmc/p/knieqjnc. To listen to the conference call on your telephone, participants may register for the

      4/22/25 8:30:00 AM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • HeartBeam to Host Fourth Quarter Full Year 2024 Results Conference Call on Thursday, March 13, 2025 at 4:30 p.m. Eastern Time

      HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, will hold a conference call on Thursday, March 13, 2025 at 4:30 p.m. Eastern time to discuss its results for the fourth quarter and full year ended December 31, 2024, and will be providing updates on regulatory initiatives, commercial-readiness activities and anticipated milestones. A press release detailing these results will be issued prior to the call. HeartBeam CEO Robert Eno and CFO Timothy Cruickshank will host the conference call, followed by a question-and-answer period. The conference call will be accompanied by a presentation, which can be

      2/27/25 8:31:00 AM ET
      $BEAT
      Medical/Dental Instruments
      Health Care

    $BEAT
    $STIM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Ferrari Richard bought $50,000 worth of shares (29,412 units at $1.70), increasing direct ownership by 20% to 179,136 units (SEC Form 4)

      4 - HeartBeam, Inc. (0001779372) (Issuer)

      2/21/25 8:00:22 PM ET
      $BEAT
      Medical/Dental Instruments
      Health Care
    • CFO Cruickshank Tim bought $30,000 worth of shares (17,647 units at $1.70) (SEC Form 4)

      4 - HeartBeam, Inc. (0001779372) (Issuer)

      2/21/25 7:55:14 PM ET
      $BEAT
      Medical/Dental Instruments
      Health Care
    • Director Cascella Robert bought $75,000 worth of shares (100,000 units at $0.75), increasing direct ownership by 28% to 453,098 units (SEC Form 4)

      4 - Neuronetics, Inc. (0001227636) (Issuer)

      9/13/24 5:02:03 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care

    $BEAT
    $STIM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • MDB Capital Holdings Provides First Quarter 2025 Update

      Addison, TX, May 21, 2025 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ:MDBH) ("MDB"), a public venture platform focused on launching category-leading disruptive technology companies, today provides an update on operations through and subsequent to the quarter ended March 31, 2025. First Quarter 2025 and Subsequent Operational Highlights Closed a public offering of common stock for HeartBeam, Inc (NASDAQ:BEAT) with gross proceeds of approximately $11.5 million. Completed LOIs for 3 new "Big Idea" companies to launch in 2025.Increased our MDBH shareholder base by 4.5% during Q1 2025.Onboarded 111 new MDB Direct accounts during the first quarter, a 26% i

      5/21/25 9:00:00 AM ET
      $BEAT
      $MDBH
      Medical/Dental Instruments
      Health Care
      Finance: Consumer Services
      Finance
    • Neuronetics Launches First Inaugural National TMS Therapy Awareness Day During Mental Health Awareness Month

      New national awareness day will foster greater understanding of transcranial magnetic stimulation (TMS) treatment The company will celebrate on social media, sharing patient and provider stories that highlight the impact NeuroStar has as a safe, effective, and non-drug treatment for depression MALVERN, Pa., May 14, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, is proud to launch the first National TMS Therapy Awareness Day. The event will take

      5/14/25 8:31:00 AM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Neuronetics Reports First Quarter 2025 Financial and Operating Results

      MALVERN, Pa., May 06, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc., (NASDAQ:STIM) (the "Company" or "Neuronetics") a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced its financial and operating results for the first quarter of 2025. First Quarter 2025 Highlights First quarter 2025 revenue of $32.0 million, an 84% increase as compared to the first quarter 2024, primarily driven by the Greenbrook acquisitionU.S. clinic revenue of $18.7 million in the quarter representing Greenbrook clinic re

      5/6/25 7:10:00 AM ET
      $STIM
      Medical/Dental Instruments
      Health Care